Dr. Eva Garland, Agile Sciences’ Vice President of Research and Development, stated, “This award speaks to the success of the Phase I studies and the potential of Agile Sciences’ technology to provide a therapeutic advantage in the treatment of lung infections in cystic fibrosis patients.”
“We are grateful to be collaborating with Dr. Boucher and Dr. Wolfgang, who are leaders in cystic fibrosis research. Their expertise will be instrumental in continuing to advance pre-clinical development of Agile Sciences’ therapeutic for cystic fibrosis,” noted Dr. Pollard.
Dr. Boucher commented, “I am pleased to participate in Agile Sciences’ NIH project. The company’s technology has the potential to address lung infections that plague cystic fibrosis patients, resulting in extensive medical treatments and hospital stays.”
This NIH STTR project will begin immediately and continue through June 30, 2016.